PL1507531T3 - Trwałe kompozycje farmaceutyczne desloratadyny - Google Patents

Trwałe kompozycje farmaceutyczne desloratadyny

Info

Publication number
PL1507531T3
PL1507531T3 PL04720451T PL04720451T PL1507531T3 PL 1507531 T3 PL1507531 T3 PL 1507531T3 PL 04720451 T PL04720451 T PL 04720451T PL 04720451 T PL04720451 T PL 04720451T PL 1507531 T3 PL1507531 T3 PL 1507531T3
Authority
PL
Poland
Prior art keywords
desloratadine
pharmaceutical compositions
stable pharmaceutical
stable
processes
Prior art date
Application number
PL04720451T
Other languages
English (en)
Inventor
Zoltan G Toth
Viktor Gyollai
Adrienne Kovacsne-Mezei
Csaba Szabo
Judith Aronhime
Claude Singer
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32996381&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1507531(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of PL1507531T3 publication Critical patent/PL1507531T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
PL04720451T 2003-03-12 2004-03-12 Trwałe kompozycje farmaceutyczne desloratadyny PL1507531T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US45429903P 2003-03-12 2003-03-12
US51535403P 2003-10-28 2003-10-28
US51690403P 2003-11-03 2003-11-03
US52633903P 2003-12-01 2003-12-01
EP04720451A EP1507531B1 (en) 2003-03-12 2004-03-12 Stable pharmaceutical compositions of desloratadine
PCT/US2004/007723 WO2004080461A2 (en) 2003-03-12 2004-03-12 Stable pharmaceutical compositions of desloratadine

Publications (1)

Publication Number Publication Date
PL1507531T3 true PL1507531T3 (pl) 2007-06-29

Family

ID=32996381

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04720451T PL1507531T3 (pl) 2003-03-12 2004-03-12 Trwałe kompozycje farmaceutyczne desloratadyny

Country Status (8)

Country Link
US (2) US20040242619A1 (pl)
EP (2) EP1507531B1 (pl)
AT (1) ATE352305T1 (pl)
DE (1) DE602004004453T2 (pl)
ES (2) ES2232331T1 (pl)
PL (1) PL1507531T3 (pl)
PT (1) PT1507531E (pl)
WO (2) WO2004108700A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
ATE352305T1 (de) * 2003-03-12 2007-02-15 Teva Pharma Stabile pharmazeutische zusammensetzungen mit desloratadine
WO2005065047A2 (en) * 2003-12-23 2005-07-21 Sun Pharmaceutical Industries Limited Stable oral composition containing desloratadine
WO2006020534A2 (en) * 2004-08-09 2006-02-23 Dr. Reddy's Laboratories Ltd. Stabilized desloratadine composition
TW200735871A (en) * 2005-11-17 2007-10-01 Teva Pharma Desloratadine crystalline forms mixtures having a low level of residual solvents
WO2007106768A2 (en) * 2006-03-14 2007-09-20 Merck & Co., Inc. Processes and apparatuses for the production of crystalline organic microparticle compositions by micro-milling and crystallization on micro-seed and their use
EP1862462A1 (en) * 2006-04-10 2007-12-05 Ranbaxy Laboratories Limited Process for the preparation of desloratadine
EP1860105A1 (en) * 2006-05-24 2007-11-28 Ranbaxy Laboratories Limited Process for the preparation of desloratadine
RU2008151047A (ru) * 2006-06-07 2010-07-20 Сандоз АГ (CH) Стабильные и биодоступные композиции и новая форма деслоратадина
WO2008107777A2 (en) * 2007-03-06 2008-09-12 Cadila Pharmaceuticals Limited Improved method for the preparation of desloratadine with reduced levels of organic solvents
MY180626A (en) 2013-11-15 2020-12-03 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
EP3638212B1 (en) * 2017-06-15 2024-05-01 Savior Lifetec Corporation Methods for producing particles of an active ingredient
CN113230235B (zh) * 2021-04-15 2022-11-11 海南普利制药股份有限公司 含地氯雷他定的复方缓释胶囊及其制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL132137C (pl) * 1963-04-24
US4282233B1 (en) * 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
HU194864B (en) * 1984-02-15 1988-03-28 Schering Corp Process for production of 8-chlor-6,11-dihydro-11-(4-piperidilidene)-5h-benzo (5,6)-cyclo-hepta (1,2-b) pyridine and its salts
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
US4826853A (en) * 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
US4863931A (en) * 1988-09-15 1989-09-05 Schering Corporation Antihistaminic fluoro substituted benzocycloheptapyridines
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
ES2042421B1 (es) * 1992-05-22 1994-08-01 Uriach & Cia Sa J Procedimiento para la obtencion de la 8-cloro-11-*1-*(5-metil-3-piridil)metil*-4-piperidiliden*-6,11-dihidro-5h-benzo*5,6*ciclohepta*1,2-b*piridina.
CA2174105C (en) * 1993-10-15 2002-02-12 W. Robert Bishop Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US7211582B1 (en) * 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
US7214683B1 (en) * 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
TW522014B (en) * 1997-02-07 2003-03-01 Sepracor Inc Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine
US6084100A (en) * 1997-05-30 2000-07-04 Medichem, S.A. Process for the preparation of loratadine
UA62976C2 (en) * 1997-07-02 2004-01-15 Schering Corp Polymorphs of 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5h-benzo[5,6]cyclohepta[1,2-b]pyridine
US6506767B1 (en) * 1997-07-02 2003-01-14 Schering Corporation 8-chloro-6,11-dihydro-11-(4-piperidylidine)-5H-benzo[5,6]cyclohepta[1-2-b] pyridine
EP0903345B1 (de) * 1997-08-08 2000-10-04 Aventis Pharma Deutschland GmbH Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
US6335347B1 (en) * 1997-10-10 2002-01-01 Schering Corporation Ethyl 4-(8-chloro-5,6-dihydro-11 H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidene carboxylate polymorph
US6132758A (en) * 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
US6100274A (en) * 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
WO2001045668A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
AU2276801A (en) * 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
US7405223B2 (en) * 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
US7678908B2 (en) * 2002-04-15 2010-03-16 Sun Pharmaceutical Industries Limited Process of preparing desaloratadine
KR20050069976A (ko) * 2002-08-05 2005-07-05 산도즈 아게 데스로라타딘 헤미푸마레이트의 신규 염 및 다형체
ATE352305T1 (de) * 2003-03-12 2007-02-15 Teva Pharma Stabile pharmazeutische zusammensetzungen mit desloratadine
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
US9682043B2 (en) * 2003-12-09 2017-06-20 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents

Also Published As

Publication number Publication date
WO2004080461A3 (en) 2004-10-28
DE602004004453D1 (de) 2007-03-15
US20040229896A1 (en) 2004-11-18
EP1507774A1 (en) 2005-02-23
ES2232332T1 (es) 2005-06-01
ES2232331T1 (es) 2005-06-01
ATE352305T1 (de) 2007-02-15
ES2232332T3 (es) 2007-08-16
EP1507531A2 (en) 2005-02-23
US20040242619A1 (en) 2004-12-02
EP1507531B1 (en) 2007-01-24
PT1507531E (pt) 2007-03-30
WO2004080461A2 (en) 2004-09-23
DE602004004453T2 (de) 2007-11-08
WO2004108700A1 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
EP1615621A4 (en) COMPOSITIONS FOR ADMINISTERING DRUG COMBINATIONS
MXPA05012026A (es) Compuestos de azaindol como inhibidores de cinasa.
TW200608973A (en) Rapamycin polymorph Ⅱ and uses thereof
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
GB0321607D0 (en) Manufacture of pharmaceutical compositions
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
UA86591C2 (ru) Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
IL173744A0 (en) Pharmaceutical compositions for intranasal administration containing an opioid
TW200613243A (en) Novel compounds
NO20092611L (no) Krystallinsk faststoff Rasagilin base
GB0320382D0 (en) Pharmaceutical compositions
GB0327723D0 (en) Pharmaceutical compositions
IL183237A0 (en) Polymorphs of memantine hydrochloride
HUP0303313D0 (en) Transdermal pharmaceutical compositions
IL173930A0 (en) Pharmaceutical compositions containing forms of r-baclofen
GB0300531D0 (en) Pharmaceutical compositions
PL1507531T3 (pl) Trwałe kompozycje farmaceutyczne desloratadyny
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
SI1620396T1 (sl) Postopek za pripravo N-substituiranih 2-cianopirolidinov
TW200531686A (en) Pharmaceutical compositions
TW200738649A (en) Calcilytic compounds
PL382842A1 (pl) Sole donepezilu odpowiednie do otrzymywania kompozycji farmaceutycznych
ZA200604874B (en) Pharmaceutical compositions
HUP0303779D0 (en) Pharmaceutical compositions for the treatment of sclerosis multiplex
TW200738674A (en) Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine